- Lower urinary tract symptoms in benign prostatic hyperplasi
Tadalafil (Adcirca®)
Non Formulary
Telmisartan
Non Formulary
Telmisartan with hydrochlorothiazide
Non Formulary
Terazosin
Non Formulary
Terazosin (Hytin®)
Non Formulary
Timolol with amiloride and hydrochlorothiazide
Non Formulary
Timolol with bendroflumethiazide
Non Formulary
Tolazoline
Non Formulary
Trandolapril (Gopten®)
Non Formulary
Trandolapril and Verapamil (Tarka®)
Non Formulary
Treprostinil
Non Formulary
Triamterene with chlortalidone
Non Formulary
Valsartan with hydrochlorothiazide
Non Formulary
Key
Restricted Drug
Unlicensed
Link to adult BNF
Link to children's BNF
Link to SPCs
Cytotoxic Drug
Controlled Drug
High Cost Medicine
Cancer Drugs Fund
NHS England
Homecare
ICB
Low carbon footprint
Medium carbon footprint
High carbon footprint
Status
Description
Medicines which are suitable for initiation and maintenance prescribing by primary and secondary care clinicians. These medicines should be initiated and prescribed within their licensed indications
Amber Specialist Initiation: Initiation and maintenance of prescribing by Specialists and transfer to Primary Care prescribing when appropriate. This may be supported by a RICaD, annotated within the formulary entry.
Amber Shared Care: Initiation and maintenance of prescribing by Specialists and transfer to Primary Care prescribing, in accordance with an ESCA, annotated within the formulary entry.
Amber Specialist Recommendation: Initiation and maintenance of prescribing in Primary Care following recommendation from a specialist.
Medicines for initiation and maintenance prescribing by Specialists (hospital or GPs with Special Interest) only
Positive NICE TA and /or awaiting local clarification on place in therapy; Please contact your Medicines Optimisation team for more information.
Non-formulary Medicines which APC/Trust DTC has actively reviewed and do not recommend for use.
